In 2003, a 19-year-old Stanford dropout named Elizabeth Holmes had a bold dream: to revolutionize healthcare. She founded Theranos, a company that promised a future where just a few drops of blood could be used to perform hundreds of medical tests — quickly, cheaply, and painlessly.
It was a dream that caught the world’s imagination. Investors rushed to fund it. Politicians and powerful figures joined its board. At its peak, Theranos was valued at $9 billion — and Elizabeth Holmes was celebrated as the next Steve Jobs.
But behind the scenes, it was all built on a lie.
The Big Promise
Holmes told investors, doctors, and the public that Theranos had invented a revolutionary device, the Edison machine, that could run hundreds of blood tests using a tiny finger-prick sample. She claimed it would make traditional blood draws, big needles, and long wait times a thing of the past.
The idea was simple, exciting, and disruptive — exactly the kind of story Silicon Valley loves. Holmes spoke passionately about empowering patients, democratizing healthcare, and saving lives. Media outlets praised her as a visionary. She graced the covers of Forbes, Fortune, and Time magazines.
Big-name investors like Rupert Murdoch, the Walton family (owners of Walmart), and others poured hundreds of millions of dollars into Theranos.
But it wasn’t just money that made Theranos look untouchable — its board of directors was packed with some of the most influential people in America. Former U.S. Secretaries of State George Shultz and Henry Kissinger, former Secretary of Defense James Mattis, former Senator Sam Nunn, and former Wells Fargo CEO Richard Kovacevich all sat on the board.
Most of them had strong political and military backgrounds but little to no experience in medicine or laboratory science. Holmes used their reputations to boost Theranos’s credibility. To many outsiders, it seemed impossible that a company surrounded by such powerful figures could be hiding a secret.
Holmes’s influence even reached the highest levels of government. In 2015, she was invited to the White House as part of President Barack Obama’s “Champions of Change” program, recognizing innovation in healthcare. That same year, then–Vice President Joe Biden visited Theranos’s labs and publicly praised the company for its cutting-edge technology — unknowingly giving further legitimacy to a system that wasn’t truly working.
To further boost its image of legitimacy, Theranos secured official certifications. Their main laboratory in Newark, California, received CLIA certification, a federal approval required to legally conduct medical testing in the United States.
They also successfully lobbied Arizona lawmakers to allow patients to get blood tests without a doctor’s order, expanding their direct-to-consumer reach. This allowed patients to get blood tests without a physician’s order — a huge win that made their model seem even more disruptive and patient-friendly.
Walgreens, impressed by these certifications, launched dozens of “Theranos Wellness Centers” inside their stores.
With glowing headlines, celebrity endorsements, and political recognition, Theranos seemed unstoppable. But under the surface, the real story was very different.
The Dark Reality
The only problem? The technology didn’t work.
Behind closed doors, Theranos employees knew that the Edison machines were wildly inaccurate. In fact, for most tests, the company secretly used traditional blood testing machines from Siemens — the same devices they claimed to have made obsolete.
Worse, patients received incorrect test results that could have had serious health consequences. Some were falsely told they had conditions like cancer or HIV. Others received false reassurances that everything was fine when it wasn’t.
Instead of being transparent about the issues, Theranos leadership hid the truth. They kept employees isolated from one another, demanded strict secrecy agreements, and threatened anyone who asked too many questions.
In public, Holmes continued to smile, speak about changing the world, and attract more money.
The Fall
The house of cards started collapsing in October 2015, when John Carreyrou from The Wall Street Journal published an explosive investigation revealing that Theranos’s technology didn’t perform as advertised. This triggered a domino effect:
- In 2016, U.S. federal health regulators banned Elizabeth Holmes from owning or operating a lab for two years.
- Walgreens, once a major Theranos partner, severed ties and shut down Theranos wellness centers inside its stores.
- The Centers for Medicare and Medicaid Services (CMS) revoked Theranos’s license for its California lab and issued heavy sanctions.
- Lawsuits piled up from investors, patients, and business partners, accusing Theranos of fraud and deception.
By 2017, Theranos was facing multiple criminal investigations. Holmes settled civil fraud charges with the U.S. Securities and Exchange Commission (SEC), agreeing to pay a fine, return millions of shares, and give up control of the company — but without admitting guilt at that time.
Finally, in 2018, federal prosecutors charged Elizabeth Holmes and Theranos’s former president, Sunny Balwani, with multiple counts of wire fraud and conspiracy to commit fraud. Theranos officially shut down later that year, marking one of the biggest collapses in Silicon Valley history.
In 2022, Elizabeth Holmes was convicted of defrauding investors and sentenced to over 11 years in prison. Balwani received an even longer sentence.
Lessons from Theranos
The story of Theranos is not just about one founder’s lies — it’s a warning about what happens when hype replaces reality in the startup world.
Investors trusted a good story without demanding proof. Regulators were slow to catch up. Media outlets celebrated a narrative without digging deeper.
Theranos reminds us that innovation is important — but trust, transparency, and evidence are even more important.
Prepared by Navruzakhon Burieva
